Matthew M Cooney

Author PubWeight™ 26.53^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.	N Engl J Med	2015	8.80
2	Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.	J Clin Oncol	2009	2.89
3	Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?	J Clin Oncol	2007	1.56
4	A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.	Thyroid	2009	1.35
5	Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.	J Clin Oncol	2010	1.23
6	Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?	J Clin Oncol	2006	1.21
7	A phase I study of sunitinib plus bevacizumab in advanced solid tumors.	Clin Cancer Res	2009	1.19
8	Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.	Cancer	2008	0.96
9	Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.	Curr Opin Hematol	2007	0.95
10	Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.	Invest New Drugs	2008	0.84
11	Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.	Invest New Drugs	2008	0.83
12	Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.	Clin Genitourin Cancer	2008	0.83
13	Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.	Cancer Chemother Pharmacol	2012	0.82
14	A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors.	Invest New Drugs	2009	0.80
15	High-grade transitional cell carcinoma and melanosis of urinary bladder: case report and review of the literature.	Urology	2008	0.80
16	A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.	Cancer Chemother Pharmacol	2011	0.79
17	Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.	Cancer Chemother Pharmacol	2008	0.78
18	A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.	Invest New Drugs	2010	0.76